Interim clinical findings showed S4V was safe in all age groups. The Food and Drug Administration (FDA) has granted Fast Track designation to Shigella4V for the prevention of shigellosis. Considered a ...
Piramal Pharma Solutions has joined forces with IntoCell to broaden its bioconjugates offering and support innovation in the field. Leveraging IntoCell's proprietary drug-linker technologies alongside ...
Often undetected until it has progressed to an advanced stage, pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer. The K-Ras mutant pancreatic cancer is one of the most common types. At ...
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary ...
WuXi Biologics and WuXi STA have established a joint venture company named WuXi XDC to provide contract development and manufacturing of bioconjugates, including antibody-drug conjugates. WuXi ...
In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Eli Lilly and Company is one of them. Eli Lilly and Company (NYSE:LLY) tops our list for being ...
BOSTON & ST. LOUIS--(BUSINESS WIRE)--Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, announced today the expansion of the leadership team to include ...
Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate ...
Landmark Bioconjugate Chemistry Papers* Paper No. of Citations J.M. Prober, G.L. Trainor, R.J. Dam, F.W. Hobbs, et al., ...
Revenue increased by 46.7% YoY to RMB 5,944 millionGross profit surged by 72.5% YoY toRMB 2,139 million, with its margin of36 ...
WASHINGTON, Dec. 8, 2022 – The Publications Division of the American Chemical Society (ACS) has appointed Theresa Reineke, Ph.D., of the University of Minnesota, Twin Cities (UMTC), as editor in chief ...